• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自纤维肉瘤细胞的针对人54000分子量纤溶酶原激活物抑制剂的单克隆抗体——抑制剂中和及一步亲和纯化

Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.

作者信息

Nielsen L S, Andreasen P A, Grøndahl-Hansen J, Huang J Y, Kristensen P, Danø K

出版信息

Thromb Haemost. 1986 Apr 30;55(2):206-12.

PMID:3520936
Abstract

Mouse monoclonal antibodies were derived against a plasminogen activator inhibitor with a mol. wt. of approximately 54,000 (54 K) from the human fibrosarcoma cell line HT-1080. Screening for hybrids producing antibodies directed against the inhibitor was performed with enzyme-linked immunosorbent assay and SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting. Four clones of hybridomas producing IgG1 antibodies were further characterized. The inhibitor was purified approximately 50-fold to homogeneity from conditioned cell culture fluid with a yield of approximately 85% by a one-step procedure using Sepharose-conjugated monoclonal antibody. In the 125I-fibrin plate assay one of the antibodies neutralized the effect of the inhibitor on urokinase-type plasminogen activator. Two of the antibodies bound complexes between urokinase-type plasminogen activator and inhibitor while the remaining two antibodies did not. The antibodies could be used for immunocytochemical localization of the inhibitor in HT-1080 cells. All four antibodies cross-reacted with a plasminogen activator inhibitor derived from cultured human umbilical cord endothelial cells.

摘要

小鼠单克隆抗体是针对一种来自人纤维肉瘤细胞系HT - 1080、分子量约为54,000(54K)的纤溶酶原激活物抑制剂产生的。通过酶联免疫吸附测定和SDS - 聚丙烯酰胺凝胶电泳(SDS - PAGE)随后进行免疫印迹,对产生针对该抑制剂抗体的杂交瘤进行筛选。对产生IgG1抗体的四个杂交瘤克隆进行了进一步表征。使用琼脂糖偶联的单克隆抗体通过一步法从条件细胞培养液中纯化该抑制剂,使其纯度提高约50倍达到均一性,产率约为85%。在125I - 纤维蛋白平板试验中,其中一种抗体中和了该抑制剂对尿激酶型纤溶酶原激活物的作用。两种抗体结合尿激酶型纤溶酶原激活物与抑制剂之间的复合物,而其余两种抗体则不结合。这些抗体可用于在HT - 1080细胞中对该抑制剂进行免疫细胞化学定位。所有四种抗体都与源自培养的人脐静脉内皮细胞的纤溶酶原激活物抑制剂发生交叉反应。

相似文献

1
Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.来自纤维肉瘤细胞的针对人54000分子量纤溶酶原激活物抑制剂的单克隆抗体——抑制剂中和及一步亲和纯化
Thromb Haemost. 1986 Apr 30;55(2):206-12.
2
Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta.用抗胎盘来源抑制剂的单克隆抗体证明血浆、血小板和内皮细胞中快速作用的纤溶酶原激活物抑制剂之间的免疫学关系。
Thromb Haemost. 1986 Apr 30;55(2):213-7.
3
Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator.用单克隆抗体纯化特异性胎盘纤溶酶原激活物抑制剂及其与纤溶酶原激活物的复合物形成
Thromb Haemost. 1985 Feb 18;53(1):122-5.
4
Monoclonal antibodies against human high molecular weight urinary urokinase: application for affinity purification of urinary prourokinase.抗人高分子量尿激酶的单克隆抗体:用于尿纤溶酶原激活剂原亲和纯化的应用
Thromb Haemost. 1986 Jun 30;55(3):347-51.
5
Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.HTC大鼠肝癌细胞纤溶酶原激活物抑制剂-1的免疫亲和纯化
Thromb Haemost. 1987 Dec 18;58(4):1017-23.
6
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.利用单克隆抗体对人肿瘤细胞系中细胞外纤溶酶原激活剂及分子量约为54,000的纤溶酶原激活剂抑制剂的激素调节作用进行研究。
Mol Cell Endocrinol. 1986 May;45(2-3):137-47. doi: 10.1016/0303-7207(86)90141-3.
7
[Isolation and characteristics of urokinase-type plasminogen activator from a culture of human embryo lung fibroblasts].[从人胚肺成纤维细胞培养物中分离尿激酶型纤溶酶原激活剂及其特性]
Mol Biol (Mosk). 1986 May-Jun;20(3):778-88.
8
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.针对黑色素瘤细胞来源的66,000分子量人纤溶酶原激活物的单克隆抗体。特异性酶抑制及一步亲和纯化。
EMBO J. 1983;2(1):115-9. doi: 10.1002/j.1460-2075.1983.tb01391.x.
9
Human articular cartilage contains an inhibitor of plasminogen activator.人体关节软骨含有纤溶酶原激活物的抑制剂。
J Rheumatol. 1988 Jul;15(7):1138-43.
10
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.来自人纤维肉瘤细胞的纤溶酶原激活物抑制剂能结合尿激酶型纤溶酶原激活物,而非其酶原。
J Biol Chem. 1986 Jun 15;261(17):7644-51.

引用本文的文献

1
Functional stability of plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1的功能稳定性
ScientificWorldJournal. 2014;2014:858293. doi: 10.1155/2014/858293. Epub 2014 Oct 15.
2
Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma.纤溶酶原激活物抑制剂1(PAI-1)A15T基因多态性与表皮生长因子受体(EGFR)突变阳性肺腺癌患者的预后相关。
Tuberc Respir Dis (Seoul). 2013 Oct;75(4):140-9. doi: 10.4046/trd.2013.75.4.140. Epub 2013 Oct 29.
3
Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.
针对尿激酶型纤溶酶原激活物的自溶环的构象特异性单克隆抗体。
Biochem J. 2011 Aug 15;438(1):39-51. doi: 10.1042/BJ20110129.
4
A novel mode of intervention with serine protease activity: targeting zymogen activation.一种具有丝氨酸蛋白酶活性的新型干预模式:靶向酶原激活。
J Biol Chem. 2009 Feb 13;284(7):4647-57. doi: 10.1074/jbc.M804922200. Epub 2008 Dec 1.
5
Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.从噬菌体展示文库中分离出的一种肽对纤溶酶原激活物抑制剂-1与低密度脂蛋白受体家族内吞受体结合的抑制作用。
Biochem J. 2006 Nov 1;399(3):387-96. doi: 10.1042/BJ20060533.
6
The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.在丝氨酸蛋白酶抑制剂型抑制剂和尿激酶受体存在的情况下,前尿激酶纤溶酶原激活系统:通过相互的酶原激活来挽救活性。
Biochem J. 2003 Apr 15;371(Pt 2):277-87. doi: 10.1042/BJ20021508.
7
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.尿激酶型纤溶酶原激活物和纤溶酶原激活物抑制剂-1在原发性乳腺癌中的预后意义
Br J Cancer. 1998 Mar;77(6):932-40. doi: 10.1038/bjc.1998.154.
8
Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.尿激酶型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物与内吞作用受体α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白及极低密度脂蛋白受体的结合涉及抑制剂中的碱性残基。
Biochem J. 1998 Jan 1;329 ( Pt 1)(Pt 1):55-63. doi: 10.1042/bj3290055.
9
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.三种人乳腺癌细胞系中的尿激酶型纤溶酶原激活与其体外侵袭性相关。
Clin Exp Metastasis. 1996 May;14(3):297-307. doi: 10.1007/BF00053903.
10
Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.人乳腺癌组织胞质提取物中尿激酶型纤溶酶原激活剂(uPA)的酶联免疫吸附测定。
Breast Cancer Res Treat. 1993 Dec;28(3):223-9. doi: 10.1007/BF00666583.